Valsartan/Hydrochlorothiazide
Brand name: Valsartan-Hydrochlorothiazide
Rank #359 of 500 drugs by total cost
$27.5M
Total Cost
510,583
Total Claims
$27.5M
Total Cost
19,091
Prescribers
$54
Cost per Claim
64,459
Beneficiaries
1,311,844
30-Day Fills
$1,440
Avg Cost/Provider
27
Avg Claims/Provider
About Valsartan/Hydrochlorothiazide
Valsartan/Hydrochlorothiazide (sold as Valsartan-Hydrochlorothiazide) was prescribed 510,583 times by 19,091 Medicare Part D providers in 2023, costing the program $27.5M. At $54 per claim, this is a relatively affordable medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 356 | Aflibercept (Eylea) | $28.0M | 10,899 |
| 357 | Fostemsavir Tromethamine (Rukobia) | $27.8M | 3,094 |
| 358 | Colchicine (Colchicine) | $27.5M | 314,046 |
| 359 | Valsartan/Hydrochlorothiazide (Valsartan-Hydrochlorothiazide) | $27.5M | 510,583 |
| 360 | Ropinirole Hcl (Ropinirole Hcl) | $27.5M | 1,204,903 |
| 361 | Trifluridine/Tipiracil Hcl (Lonsurf) | $27.3M | 2,430 |
| 362 | Memantine Hcl/Donepezil Hcl (Namzaric) | $27.2M | 46,134 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology